Literature DB >> 30150474

Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantification of Olorofim (F901318), a Novel Antifungal Drug, in Human Plasma and Serum.

Carsten Müller1, Cornelia Fietz2, Philipp Koehler3,4, Graham Sibley5, Achu Che Awah Nforbugwe6, Thomas Streichert6, Martin H J Wiesen2.   

Abstract

A fast and easy-to-use liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination and quantification of a novel antifungal drug, olorofim (F901318), a member of the novel class of orotomides, in human plasma and serum was developed and validated. Sample preparation was based on protein precipitation with acetonitrile and subsequent centrifugation. An isotope-labeled analogue of F901318 was employed as an internal standard. Chromatographic separation was achieved using a 50-mm by 2.1-mm, 1.9-μm, polar Hypersil Gold C18 column and isocratic mobile phase consisting of 0.1% formic acid-acetonitrile (60%-40%, vol/vol) at a flow rate of 330 μl/min. The analyte was detected using a triple-stage quadrupole mass spectrometer operated in selected reaction monitoring (SRM) mode with positive heated electrospray ionization (HESI+) within a single runtime of 2.00 min. The present LC-MS/MS method was validated according to the international guidelines of the International Conference on Harmonisation (ICH) and the U.S. Food and Drug Administration (FDA). Linearity of F901318 concentration ranges was verified by the Mandel test. The calibration curve was tested linear across the range and fitted using least-squares regression with a weighting factor of the reciprocal concentration. The limit of detection was 0.0011 mg/liter, and the lower limit of quantitation was 0.0033 mg/liter. Intraday and interday precisions ranged from 1.17% to 3.23% for F901318, and intraday and interday accuracies (percent bias) ranged from 0.75% to 5.01%. In conclusion, a method was established for the rapid quantitation of F901318 concentrations in serum and plasma samples in patient trials, and it optimizes therapeutic drug monitoring in applying an easy-to-use single method.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  antifungal agents; antifungal drug; liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS); matrix effects; orotomide; therapeutic drug monitoring

Mesh:

Substances:

Year:  2018        PMID: 30150474      PMCID: PMC6201104          DOI: 10.1128/AAC.01356-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.

Authors:  Jason D Oliver; Graham E M Sibley; Nicola Beckmann; Katharine S Dobb; Martin J Slater; Laura McEntee; Saskia du Pré; Joanne Livermore; Michael J Bromley; Nathan P Wiederhold; William W Hope; Anthony J Kennedy; Derek Law; Mike Birch
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-25       Impact factor: 11.205

2.  Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans.

Authors:  Nathan P Wiederhold; Derek Law; Michael Birch
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

3.  In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.

Authors:  J B Buil; A J M M Rijs; J F Meis; M Birch; D Law; W J G Melchers; P E Verweij
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

4.  In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi.

Authors:  Chayanika Biswas; Derek Law; Michael Birch; Catriona Halliday; Tania C Sorrell; John Rex; Monica Slavin; Sharon C-A Chen
Journal:  Med Mycol       Date:  2018-11-01       Impact factor: 4.076

Review 5.  The antifungal arsenal: alternative drugs and future targets.

Authors:  Nathan P Wiederhold
Journal:  Int J Antimicrob Agents       Date:  2017-09-07       Impact factor: 5.283

6.  Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.

Authors:  William W Hope; Laura McEntee; Joanne Livermore; Sarah Whalley; Adam Johnson; Nicola Farrington; Ruwanthi Kolamunnage-Dona; Julie Schwartz; Anthony Kennedy; Derek Law; Michael Birch; John H Rex
Journal:  mBio       Date:  2017-08-22       Impact factor: 7.867

Review 7.  Antifungal resistance: current trends and future strategies to combat.

Authors:  Nathan P Wiederhold
Journal:  Infect Drug Resist       Date:  2017-08-29       Impact factor: 4.003

8.  Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.

Authors:  Clara E Negri; Adam Johnson; Laura McEntee; Helen Box; Sarah Whalley; Julie A Schwartz; V Ramos-Martín; Joanne Livermore; Ruwanthi Kolamunnage-Dona; Arnaldo L Colombo; William W Hope
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

  8 in total
  2 in total

Review 1.  The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.

Authors:  Martin Hoenigl; Rosanne Sprute; Matthias Egger; Amir Arastehfar; Oliver A Cornely; Robert Krause; Cornelia Lass-Flörl; Juergen Prattes; Andrej Spec; George R Thompson; Nathan Wiederhold; Jeffrey D Jenks
Journal:  Drugs       Date:  2021-10-09       Impact factor: 9.546

Review 2.  Hope on the Horizon: Novel Fungal Treatments in Development.

Authors:  Adriana M Rauseo; Ariella Coler-Reilly; Lindsey Larson; Andrej Spec
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.